Journal
CHINESE MEDICAL JOURNAL
Volume 135, Issue 4, Pages 393-399Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CM9.0000000000001929
Keywords
IL-2; IL-15; IL-10; IL-18; Melanoma; Immunotherapy
Categories
Funding
- National Defense Science and Technology Excellence Youth Talent Foundation of China [2018-JCJQ-ZQ-006]
- National Natural Science Foundation of China [82103379]
Ask authors/readers for more resources
This article introduces the use of ILs to modulate the immune system in cancer treatment and discusses their application in the treatment of melanoma. It also mentions the potential synergy between ILs and immune checkpoint inhibition for better clinical outcomes.
Interleukins (ILs) and associated cytokines serve as the means of communication for immune cells and non-immune cells. The use of ILs in harnessing the immune system to cancer treatment has been a promising approach. ILs not only nurture an environment enabling cancer growth but also simultaneously trigger a productive tumor-directed immune response. These properties of ILs are increasingly being explored as a strategy to improve the outcomes of cancer. Here, we describe recently innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacies of IL-2, 15, 10, and 18 in the treatment of melanoma. Furthermore, the combination of ILs and immune checkpoint inhibition may synergize to reshape the tumor environment, thus yielding better clinical benefits in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available